John Strang1, Rebecca McDonald2, Abdulmalik Alqurshi3, Paul Royall4, David Taylor5, Ben Forbes6. 1. National Addiction Centre, Addictions Department, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, 4 Windsor Walk, Denmark Hill, London SE5 8BB, UK. Electronic address: john.strang@kcl.ac.uk. 2. National Addiction Centre, Addictions Department, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, 4 Windsor Walk, Denmark Hill, London SE5 8BB, UK. Electronic address: rebecca.s.mcdonald@kcl.ac.uk. 3. Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, UK. Electronic address: abdul.al_qurshi@kcl.ac.uk. 4. Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, UK. Electronic address: paul.royall@kcl.ac.uk. 5. Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, UK; Pharmacy Department, South London and Maudsley NHS Foundation Trust (SLaM), Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK. Electronic address: david.taylor@slam.nhs.uk. 6. Institute of Pharmaceutical Science, King's College London, 150 Stamford Street, London SE1 9NH, UK. Electronic address: ben.forbes@kcl.ac.uk.
Abstract
INTRODUCTION: Deaths from opioid overdose can be prevented through administration of the antagonist naloxone, which has been licensed for injection since the 1970s. To support wider availability of naloxone in community settings, novel non-injectable naloxone formulations are being developed, suitable for emergency use by non-medical personnel. OBJECTIVES: 1) Identify candidate routes of injection-free naloxone administration potentially suitable for emergency overdose reversal; 2) consider pathways for developing and evaluating novel naloxone formulations. METHODS: A three-stage analysis of candidate routes of administration was conducted: 1) assessment of all 112 routes of administration identified by FDA against exclusion criteria. 2) Scrutiny of empirical data for identified candidate routes, searching PubMed and WHO International Clinical Trials Registry Platform using search terms "naloxone AND [route of administration]". 3) Examination of routes for feasibility and against the inclusion criteria. RESULTS: Only three routes of administration met inclusion criteria: nasal, sublingual and buccal. Products are currently in development and being studied. Pharmacokinetic data exist only for nasal naloxone, for which product development is more advanced, and one concentrated nasal spray was granted licence in the US in 2015. However, buccal naloxone may also be viable and may have different characteristics. CONCLUSION: After 40 years of injection-based naloxone treatment, non-injectable routes are finally being developed. Nasal naloxone has recently been approved and will soon be field-tested, buccal naloxone holds promise, and it is unclear what sublingual naloxone will contribute. Development and approval of reliable non-injectable formulations will facilitate wider naloxone provision across the community internationally.
INTRODUCTION: Deaths from opioid overdose can be prevented through administration of the antagonist naloxone, which has been licensed for injection since the 1970s. To support wider availability of naloxone in community settings, novel non-injectable naloxone formulations are being developed, suitable for emergency use by non-medical personnel. OBJECTIVES: 1) Identify candidate routes of injection-free naloxone administration potentially suitable for emergency overdose reversal; 2) consider pathways for developing and evaluating novel naloxone formulations. METHODS: A three-stage analysis of candidate routes of administration was conducted: 1) assessment of all 112 routes of administration identified by FDA against exclusion criteria. 2) Scrutiny of empirical data for identified candidate routes, searching PubMed and WHO International Clinical Trials Registry Platform using search terms "naloxone AND [route of administration]". 3) Examination of routes for feasibility and against the inclusion criteria. RESULTS: Only three routes of administration met inclusion criteria: nasal, sublingual and buccal. Products are currently in development and being studied. Pharmacokinetic data exist only for nasal naloxone, for which product development is more advanced, and one concentrated nasal spray was granted licence in the US in 2015. However, buccal naloxone may also be viable and may have different characteristics. CONCLUSION: After 40 years of injection-based naloxone treatment, non-injectable routes are finally being developed. Nasal naloxone has recently been approved and will soon be field-tested, buccal naloxone holds promise, and it is unclear what sublingual naloxone will contribute. Development and approval of reliable non-injectable formulations will facilitate wider naloxone provision across the community internationally.
Authors: Joanne Neale; Adrian Farrugia; Aimee N Campbell; Paul Dietze; Robyn Dwyer; Renae Fomiatti; Jermaine D Jones; Sandra D Comer; Suzanne Fraser; John Strang Journal: Drugs (Abingdon Engl) Date: 2021-02-22
Authors: Johanna Tuunainen; Lasse Saloranta; Jouko Levijoki; Jenni Lindstedt; Jenni Lehtisalo; Sari Pappinen; Meri Ramela; Sami Virtanen; Heikki Joensuu Journal: Pharmaceuticals (Basel) Date: 2022-04-25
Authors: Randy So; Yazid Al Hamarneh; Mark Barnes; Michael A Beazely; Michael Boivin; Julie Laroche; Harsit Patel; Aaron Sihota; Tim Smith; Ross T Tsuyuki Journal: Can Pharm J (Ott) Date: 2020-09-21
Authors: Vanessa M McMahan; Justine Arenander; Tim Matheson; Audrey M Lambert; Sarah Brennan; Traci C Green; Alexander Y Walley; Phillip O Coffin Journal: JMIR Form Res Date: 2022-09-07